Cencora Announces Q3 Fiscal 2024 Earnings Release Date and Conference Call Cencora, Inc. (NYSE: COR) has announced plans to release its Third Quarter Fiscal 2024 results on Wednesday, July 31,…
MDPI is delighted to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has…
Navidea Biopharmaceuticals, Inc. a company specializing in precision immunodiagnostic agents and immunotherapeutics, has disclosed disappointing findings from an exploratory analysis conducted on its pivotal NAV3-33 clinical trial, titled “Evaluation of…
The United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for treating neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic…
Genexine (KOSDAQ: 095700), a Korean clinical-stage biopharmaceutical firm dedicated to developing innovative biologics for critical medical needs, has announced a merger with EPD Biotherapeutics (referred to as ‘EPD Bio’), a…
The ‘In Vitro Diagnostic Collaboration and Licensing Deals 2016-2024’ report offers an extensive analysis and unprecedented access to collaboration and licensing agreements in the global biopharma industry. Updated and meticulously…
Owkin, the first end-to-end AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has announced its expansion into the DACH region (Germany, Austria, and Switzerland). This follows partnerships…
During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy to a start-up that exemplifies the region’s innovation and richness. French Tech…
The Antibiotic Collaboration and Licensing Deals 2016-2024 report has been added to ResearchAndMarkets.com’s offerings. This report provides a comprehensive understanding and unprecedented access to antibiotic deals made by the world’s…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that its Phase II/III SKYSCRAPER-06 study did not achieve its primary endpoints in evaluating tiragolumab in…
BenevolentAI (Euronext Amsterdam: BAI), a pioneering force in applying advanced artificial intelligence (AI) to expedite biopharma drug discovery, has announced changes to its Executive Leadership Team (ELT) following the recent…
Owkin, the pioneering AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has launched its expansion into the DACH region (Germany, Austria, and Switzerland). This expansion follows strategic…